Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) is a biopharmaceutical company developing conditionally activated immune therapies for cancer and other immune-mediated conditions. Its proprietary PREDATOR platform is designed to keep therapeutic molecules inactive in circulation and activate them in the tumor… From the company’s description.
Over the twelve months to Jun 30, 2026, Werewolf Therapeutics, Inc. reported revenue of $21.00M and a net loss of $34.61M. Its operating margin was −148.8%, and operations used $30.15M in cash. In fiscal 2025, it reported a net loss of $60.82M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Werewolf Therapeutics, Inc. does
In the company’s own words
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) is a biopharmaceutical company developing conditionally activated immune therapies for cancer and other immune-mediated conditions. Its proprietary PREDATOR platform is designed to keep therapeutic molecules inactive in circulation and activate them in the tumor microenvironment. The pipeline includes INDUKINE cytokine candidates WTX-124 (IL-2) and WTX-330 (IL-12), which are in clinical development, and preclinical candidates targeting IL-21, IL-18 and IL-10. Its INDUCER program uses the platform to develop T-cell engagers, including preclinical candidates targeting STEAP1 and CDH6. The company’s lead candidates are intended for patients with advanced or metastatic tumors; WTX-921 is being developed for inflammatory bowel disease and potentially other inflammatory diseases. Werewolf has licensed global development and commercialization rights to its IFNα INDUKINE, JZP898, to Jazz Pharmaceuticals. In February 2026, it adopted a restructuring plan and began exploring strategic alternatives for its platform and pipeline.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 1785530
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Werewolf Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Werewolf Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Werewolf Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Werewolf Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Werewolf Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”